As leaders in cardiology, the physicians at Carient are committed to continuing their education and growing their understanding of the best practices and treatments. Often, this new knowledge comes about through clinical research, which is why our team at Carient is dedicated to conducting and participating in research protocols. The insights revealed through clinical research will enable our patients to obtain the newest treatments before they are available to the general public. Carient is one of the few sites in Northern Virginia that participates in large cardiovascular clinical trials that are otherwise only available to major academic centers.
Carient’s physicians are honored to participate in vital and impactful clinical research in the field of cardiology. This research ultimately leads to new advancements in the care we provide our patients. We have been one of only a few sites elected to participate in several elite research studies and new interventional devices and procedures.
The Clinical Research Institute at Carient was established in 2010 under the supervision of Dr. Hamid Taheri. We have participated in over 25 large clinical trials. Our patients have access to new treatments and we have been recognized nationally for our successful enrollment.
We are currently accepting new patients into the following studies:
Evaluating the effectiveness of a lipid lowering self-injection every 2 weeks.
Criteria: Experienced a heart attack in the past year and LDL >70.
Evalluating an approved weight loss drug (Belviq) in patient at high-risk for cardiovascular events. Criteria: Cardiovascular disease or Multiple Risk Factors.
Evaluating an approved diabetic medication (Dapagliflozin) in patients with Diabetes and Cardiovascular Disease.
Criteria: Patient’s who have a history of a heart attack or have 2 vessel coronary arteries disease and also have Diabetes.
Evaluating the effectiveness of anti-inflammatory therapy with low dose methotrexate vs placebo in reducing cardiovascular outcomes.
Criteria: Experienced a heart attack in the past 5 years and have Diabetes.
An atrial fibrillation registry comparing long term anti-thrombotic treatments.
Criteria: New onset Atrial Fibrillation diagnosed in the past 3 months and prescribed anticoagulation therapy.
REDUCE-IT (AMR 01-001)
Evaluating the effect of this 96% pure form Omega 3 Triglyceride medication on the health and mortality of hypertriglyceridemic patients with cardiovascular disease or at high risk.
Criteria: Patients with cardiovascular disease or at high risk with untreated Triglycerides levels >200.
Treatment Strategies with Xeralto vs. Coumadin in patients with Atrial Fibrillation who undergo angioplasty.
Criteria: Patient must have Atrial Fibrillation and enroll in the study within 72 hours of angioplasty.
Registry for the clinical management of patients 1-3 years post heart attack. Criteria: Heart attach 1-3 years ago with multiple risk factors.
Please contact us for more information or if you are interested in participating in a studies